Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2506 to 2520 of 8905 results

  1. Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]

    In development Reference number: GID-TA10575 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407]

    In development Reference number: GID-TA11498 Expected publication date:  29 April 2026

    Technology appraisal guidance
    In development

  3. Suspected sepsis in pregnancy: recognition, diagnosis and early management

    In development Reference number: GID-NG10468 Expected publication date:  17 February 2027

    NICE guideline
    In development

  4. Pharmalgen for the treatment of bee and wasp venom allergy

    In development Reference number: GID-TA11898 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Seladelpar for previously treated primary biliary cholangitis [ID6429]

    In development Reference number: GID-TA11540 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA779) [ID6326]

    In development Reference number: GID-TA11764 Expected publication date:  23 July 2026

    Technology appraisal guidance
    In development

  7. Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]

    In development Reference number: GID-TA11220 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Nivolumab in combination for untreated advanced classical Hodgkin lymphoma in people 12 years and over [ID6690]

    Awaiting development Reference number: GID-TA11908 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Nivolumab + Brentuximab vedotin for Hodgkin lymphoma [ID6691]

    Awaiting development Reference number: GID-TA11909 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Prognostic tests for multiple myeloma

    Awaiting development Reference number: GID-HTG10153 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  11. Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update)

    In development Reference number: GID-NG10216 Expected publication date:  15 July 2026

    NICE guideline
    In development

  12. Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update): draft guidance consultation

    We are listening to your views on this NICE guideline. Comments close 23 February 2026.

    NICE guideline
    In consultation

  13. Obinutuzumab for treating childhood-onset idiopathic nephrotic syndrome in people 2 years and over [ID6692]

    Awaiting development Reference number: GID-TA11910 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Medicines for treating osteoporosis and reducing the risk of fragility fractures (review of TA160, TA161, TA204, TA464, TA791, TA991) [ID6689]

    Awaiting development Reference number: GID-TA11907 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Linvoseltamab for treating relapsed or refractory multiple myeloma after 3 or more treatments [ID6609]

    Awaiting development Reference number: GID-TA11052 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development